The combination of IFN-α2 and IFN-α8 exhibits synergistic antiproliferative activity on renal cell carcinoma (RCC) cell lines through increased binding affinity for IFNAR-2

Journal of Interferon and Cytokine Research

Volumn 27, Issue 6, 2007, Pages 517-523

  Tanimoto, Tadao ^a   Yamamoto, Shigeto ^a   Taniai, Madoka ^a   Taniguchi, Mutsuko ^a   Ariyasu, Harumi ^a   Ushio, Chie ^a   Aga, Miho ^a   Mukai, Yohei ^b   Tsutsumi, Yasuo ^c   Ariyasu, Toshio ^a   Ohta, Tsunetaka ^a   Fukuda, Shigeharu ^a  

^a HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON 8; ALPHA INTERFERON DERIVATIVE; ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 2; ALPHA1 INTERFERON RECEPTOR; ALPHA2 INTERFERON; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; IFNAR2 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; BIOSENSOR; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; KIDNEY CARCINOMA; PRIORITY JOURNAL; RECEPTOR BINDING; SURFACE PLASMON RESONANCE; CLASSIFICATION; DRUG EFFECT; KINETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERFERON-ALPHA; KINETICS; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 34250877369     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0155     Document Type: Article

References (35)

1. Yamamoto S, Yano H, Sanou O, Ikegami H, Kurimoto M, Kojiro M. Different antiviral activities of IFN-α subtypes in human liver cell lines: synergism between IFN-α2 and IFN-α8. Hepat. Res. 2002;24:99-106.
2. Yanai Y, Sanou O, Kayano T, Ariyasu H, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M. Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J. Interferon Cytokine Res. 2001;21:835-841.
3. Yanai Y, Horie S, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M, Kitamura T. Characterization of the antitumor activities of IFN-α8 on renal cell carcinoma cells in vitro. J. Interferon Cytokine Res. 2001;21:1129-1136.
4. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J, Boll W, Cantell K, Weissmann C. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980;284:316-320.
5. Hobb DS, Moschera JA, Levy WP, Pestka S. Purification of interferon produced in a culture of human granulocytes. Methods Enzymol. 1981;78:472-481.
6. Henco K, Brosius J, Fujisawa A, Fujisawa JI, Haynes JR, Hochstadt J, Kovacic T, Pasek M, Schambock A, Schmid J, Todokoro K, Walchli M, Nagata S, Weissmann C. Structural relationship of human interferon alpha genes and pseudogenes. J. Mol. Biol. 1985;185:227-260.
7. Diaz MO, Bohlander S, Allen G. Nomenclature of the human interferon genes. J. Interferon Cytokine Res. 1996;16:179-180.
8. Cleary CM, Donnelly RJ, Soh J, Mariano TM, Pestka S. Knockout and reconstitution of a functional human type I interferon receptor complex. J. Biol. Chem. 1994;269:18747-18749.
9. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uzé G. The type I interferon receptor: structure, function, and evolution of a family business. J. Interferon Cytokine Res. 1999;19:1069-1098.
10. Benoit P, Maguire D, Plavec I, Kocher H, Tovey M, Meyer R. A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J. Immunol. 1993;150:707-716.
11. Fish EN, Banerjee K, Stebbing N. The role of three domains in the biological activity of human interferon-α. J. Interferon. Res. 1989;9:97-114.
12. Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 1994;77:391-400.
13. Bisat F, Raj NB, Pitha PM. Differential and cell type specific expression of murine alpha-interferon genes is requlated on the transcriptional level. Nucleic. Acids Res. 1988;16:6067-6083.
14. Castelruiz Y, Larrea E, Boya P, Civeira MP, Prieto J. Interferon alpha subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatology 1999;29:1900-1904.
15. Evinger M, Rubinstein M, Pestka S. Antiproliferative and antiviral activities of human leukocyte interferons. Arch. Biochem. Biophys. 1981;210:319-329.
16. Fish EN, Banerjee K, Stebbing N. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem. Biophys. Res. Commun. 1983;112:537-546.
17. Ortaldo JR, Herberman RB, Harvey C, Osheroff P, Pan YC, Kelder B, Pestka S. A species of human alpha interferon that lacks the ability to boost human natural killer activity. Proc. Natl. Acad. Sci. USA 1984;81:4926-4929.
18. Greiner JW, Fisher PB, Pestka S, Schlom J. Differential effects of recombinant human leukocyte interferons on cell surface antigen expression. Cancer Res. 1986;46:4984-4990.
19. Yanai Y, Sanou O, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M. The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes. Cancer Lett. 2002;185:173-179.
20. Ariyasu T, Fujioka N, Yamamoto S, Yanai Y, Yamauchi H, Ikegami H, Ikeda M, Kurimoto M, Horie S, Kitamura T. Correlation between interferon alpha receptor protein expression and sensitivity to interferon alpha subtypes in human renal carcinoma cell lines. Cancer Genom. Proteom. 2004;1:87-94.
21. Foster GR, Rodrigues O, Ghouze F, Schulte-Frohlinde E, Testa D, Liao MJ, Stark GR, Leadbeater L, Thomas HC. Different relative activities of human cell-derived interferon-α subtypes: IFN-α8 has very high antiviral potency. J. Interferon Cytokine Res. 1996;16:1027-1033.
22. Fukuda S, Ando S, Sanou O, Taniai M, Fujii M, Masaki N, Nakamura K, Ando O, Torigoe K, Sugimoto T, Kurimoto M. Simultaneous production of natural human tumor necrosis factor-α, -β and interferon-α from BALL-1 cells stimulated by HVJ. Lymphokine Res. 1988;7:175-185.
23. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 1973;51:1417-1423.
24. Chang AY, Keng PC. Inhibition of cell growth in synchronous human hypernephroma cells by recombinant interferon-αD and irradiation. J. Interferon Res. 1983;3:379-385.
25. Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 1977;58:209-214.
26. Naito S, Kotoh S, Goto K, Koga H, Hasegawa S, Noma H, Yamasaki T, Kumazawa J. Establishment of two human renal cell carcinoma cell lines with different chemosensitivity. Hum. Cell 1996;9:101-108.
27. Naito S, Kanamori T, Hisano S, Tanaka K, Momose S, Kamata N. Human renal cell carcinoma: establishment and characterization of two new cell lines. J. Urol. 1982;128:1117-1121.
28. Miyao N, Tsukamoto T, Kumamoto Y. Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2, and SMKT-R-3) and their characters. Urol. Res. 1989;17:317-324.
29. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC, eds. Synergism and Antagonism in Chemotherapy. San Diego: Academic Press, 1991:61-102.
30. Chuntharapai A, Gibbs V, Lu J, Ow A, Marsters S, Ashkenazi A, De Vos A, Kim KI. Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2. J. Immunol. 1999;163:766-773.
31. Lu I, Chuntharapai A, Beck I, Bass S, Ow A, De Vos AM, Gibbs V, Kim KI. Structure-function study of the extracellular domain of the human IFN-alpha receptor (MFNAR1) using blocking monoclonal antibodies: the role of domains 1 and 2. J. Immunol. 1998;160:1782-1788.
32. Tsuji A, Maeda M. Detection methods for immunoassay. In: Kitagawa T, Nambara T, Tsuji A, Ishikawa E, eds. Protein, Nucleic Acid and Enzyme. Tokyo: Kyoritsu Shuppan, 1987:51-63.
33. Lutfalla G, Holland SI, Cinato E, Monneron D, Reboul J, Rogers NC, Smith IM, Stark GR, Gardiner K, Mogensen KE, Kerr IM, Uzé G. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 1995;14:5100-5108.
34. Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, Pitha P, Colamonici OR. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J. Biol. Chem. 1995;270:21606-21611.
35. Domanski P, Colamonici OR. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev. 1996;7:143-151.